Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Medicenna Therapeutics Corp. (MDNA)

1.1   0.02 (1.85%) 05-18 01:32
Open: 1.24 Pre. Close: 1.08
High: 1.24 Low: 1.06
Volume: 26,203 Market Cap: 62(M)
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.24 - 1.25 1.25 - 1.25
Low: 1.05 - 1.05 1.05 - 1.06
Close: 1.09 - 1.1 1.1 - 1.11

Technical analysis

as of: 2022-05-17 4:48:36 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.35     One year: 1.54
Support: Support1: 0.91    Support2: 0.75
Resistance: Resistance1: 1.16    Resistance2: 1.32
Pivot: 1.07
Moving Average: MA(5): 1.04     MA(20): 1.09
MA(100): 1.43     MA(250): 2.1
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 50.6     %D(3): 39.3
RSI: RSI(14): 47.2
52-week: High: 4.01  Low: 0.91
Average Vol(K): 3-Month: 116 (K)  10-Days: 99 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MDNA ] has closed below upper band by 41.3%. Bollinger Bands are 31.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 17 May 2022
Successful Restart of Prowein 2022 - wineindustryadvisor.com

Mon, 16 May 2022
Taking Beauty Advice From A Matchmaker Just Makes Sense - Refinery29

Fri, 13 May 2022
Short Interest in Medicenna Therapeutics Corp. (NASDAQ:MDNA) Expands By 138.5% - Defense World

Wed, 11 May 2022
Medicenna Therapeutics (MDNA) Reports Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinical Profile - StreetInsider.com

Thu, 05 May 2022
TRENDING: OVERNIGHT CARAVAN STAYS WITH VINTNERS - Food & Beverage Magazine - Food & Beverage Magazine

Thu, 05 May 2022
Medicenna Therapeutics (TSE:MDNA) Coverage Initiated by Analysts at Maxim Group - Defense World

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 54 (M)
Shares Float 39 (M)
% Held by Insiders 33.2 (%)
% Held by Institutions 7.3 (%)
Shares Short 262 (K)
Shares Short P.Month 223 (K)

Stock Financials

EPS -0.39
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.46
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -50.2
Return on Equity (ttm) -87.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.47
Qtrly Earnings Growth 0
Operating Cash Flow -23 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -2.85
PEG Ratio 0
Price to Book value 2.39
Price to Sales 0
Price to Cash Flow -2.6

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.